TerminatedPhase 3NCT05695391
A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM
Studying Hemophilia A
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
- Principal Investigator
- Miguel ESCOBAR, MDThe University of Texas Health Science Center, Houston
- Intervention
- Coagulation Factor VIIa (Recombinant)(biological)
- Enrollment
- 2 enrolled
- Eligibility
- 12-65 years · MALE
- Timeline
- 2024 – 2025
Study locations (15)
- Orthopaedic Institute for Children - Orthopaedic Hemophilia Treatment Center, Los Angeles, California, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- Tulane Univertsity School of Medecine, New Orleans, Louisiana, United States
- M Health Fairview Center for bleeding and Clotting disorders, Minneapolis, Minnesota, United States
- University of Texas Health Science Center at Houston, Houston, Texas, United States
- Hospital Queen Elisabeth - Kota Kinabalu, Kota Kinabalu, Sabah Province, Malaysia
- Hospital Ampang, Ampang, Selangor Province, Malaysia
- Hospital Universitario Dr. José Eleuterio González de Nuevo León, Monterrey, Nuevo León, Mexico
- Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, Gauteng, South Africa
- Chiang Mai University, Chiang Mai, Thailand
- Maharaj Nakorn Chiangmai Hospital, Chiangmai University, Chiang Mai, Thailand
- Acibadem Adana Hospital, Seyhan, Adana, Turkey (Türkiye)
- Hacettepe Üniversitesi Rektörlüğü Sihhiye, Altındağ, Ankara, Turkey (Türkiye)
- Istanbul Üniversitesi Onkoloji Enstitusu, Fatih, Istanbul, Turkey (Türkiye)
- Karadeniz Teknik Üniversitesi, Trabzon, Trabzon, Turkey (Türkiye)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05695391 on ClinicalTrials.govOther trials for Hemophilia A
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT05936580Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for SurgeryOctapharma
- ACTIVE NOT RECRUITINGNCT07161687A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.Pfizer
- RECRUITINGPHASE4NCT06864975Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)Runhui WU
- RECRUITINGPHASE1NCT06579144Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia ASwedish Orphan Biovitrum
- RECRUITINGPHASE3NCT06738485Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCSL Behring
- RECRUITINGNCT06684314A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in TaiwanSanofi
- RECRUITINGNCT07414511Hemophilia A Research ProgramUniversity of Washington
- RECRUITINGEARLY PHASE1NCT06345833Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded StudyUniversity of Minnesota